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Abstract

Background: In addition to the contraceptive action of the combined oral contraceptive pill (COCP), there
are a number of other benefits to its use such as menstrual cycle regulation. However, COCP use is also
associated with a higher risk of thromboembolism. Despite the prevalence of COCP use, studies have
indicated that overall women have poor knowledge of the COCP.
Aim: To evaluate women's knowledge of the COCP in a rural general practice setting. The extent of
knowledge was assessed in several domains including: COCP use and effectiveness, mechanism of action, and
the risks and benefits of COCP use.
Methods: An observational study design was utilised. Women aged 18-50 years self-selected to complete an
anonymous survey at a general practice in rural NSW. Women who were currently using, had previously used,
or had never used the COCP were invited to participate. Women using a progesterone-only contraceptive
were excluded. A total knowledge score on the usage and effects of the COCP was calculated for each
participant by assessing responses to 34 questions for an overall score out of 34.
Results: A total of 80 surveys were completed revealing that 98% of respondents used the COCP at some
time in their lives with almost 29% being current users. The mean total knowledge score for all participants
was 14.4 (SD = 4.9) out of a possible 34 (range: 5 - 26). There was no significant difference in total knowledge
score between current and previous users (p = 0.56).
Conclusion: The women surveyed in this study appear to have substantial gaps in their knowledge of the
COCP. This study provides insight into specific knowledge areas that require further education and
clarification during COCP counselling sessions (especially those conducted by a GP) to encourage improved
knowledge of the COCP by women in this particular setting.
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Abstract
Background: In addition to the contraceptive action of the combined
oral contraceptive pill (COCP), there are a number of other benefits
to its use such as menstrual cycle regulation. However, COCP use
is also associated with a higher risk of thromboembolism. Despite
the prevalence of COCP use, studies have indicated that overall
women have poor knowledge of the COCP.
Aim: To evaluate women’s knowledge of the COCP in a rural general
practice setting. The extent of knowledge was assessed in several
domains including: COCP use and effectiveness, mechanism of
action, and the risks and benefits of COCP use.
Methods: An observational study design was utilised. Women aged
18-50 years self-selected to complete an anonymous survey at a
general practice in rural NSW. Women who were currently using,
had previously used, or had never used the COCP were invited to
participate. Women using a progesterone-only contraceptive were
excluded. A total knowledge score on the usage and effects of the
COCP was calculated for each participant by assessing responses to
34 questions for an overall score out of 34.
Results: A total of 80 surveys were completed revealing that 98%
of respondents used the COCP at some time in their lives with
almost 29% being current users. The mean total knowledge score
for all participants was 14.4 (SD = 4.9) out of a possible 34 (range:
5 - 26). There was no significant difference in total knowledge score
between current and previous users (p = 0.56).
Conclusion: The women surveyed in this study appear to have
substantial gaps in their knowledge of the COCP. This study provides
insight into specific knowledge areas that require further education
and clarification during COCP counselling sessions (especially those
conducted by a GP) to encourage improved knowledge of the COCP
by women in this particular setting.

Introduction
The combined oral contraceptive pill (COCP) is an oral hormonal
contraceptive that contains synthetic oestrogen and progesterone.
Since it was first made available in Australia in 1961, the COCP has
become the principal contraceptive method of choice among Australian
women [1]. Contraceptive management is a common reason for GP
consultation, with the COCP being the most frequently prescribed
contraceptive [1].
Though it is well known for its contraceptive action, there are a
number of additional benefits associated with COCP use [2-11]. There
is decreased risk of ovarian and endometrial cancers [2,3,5,6] and
reduced risk of benign breast disease, functional ovarian cysts, ectopic
pregnancies, and pelvic inflammatory disease [2-4,7]. The COCP is
also beneficial in that it helps to regulate the menstrual cycle, and
reduces dysmenorrhoea, menorrhagia, and endometriosis-associated
pain [2,3,8,9]. Acne and the effects of hyperandrogenism may also be
minimised with COCP use [2-4,10].

Despite these many benefits, there are several risks associated with
COCP use. The introduction of low-dose COCPs saw a significant
improvement in its safety profile, particularly in the reduction of
thromboembolism [2,3]. Nonetheless, COCP use does increase the risk
of thromboembolism, stroke, and myocardial infarction [2,3,12,13].
This is a rare complication in otherwise healthy women [2]. Women
over the age of 35, smokers, and women who are obese have a higher
risk of thromboembolism with COCP use [11,14]. The evidence is mixed
as to whether the COCP increases the risk of breast cancer [2,15]. The
current consensus is that the COCP does increase risk, but this risk is
considered to be very small (equal to approximately one extra case per
year for every 100,000 women) and becomes negligible ten years after
cessation of use [15,16], however, research is still ongoing.
The COCP has been shown to be a very effective contraceptive with
perfect use (the failure rate is 0.3%), however, its typical-use failure
rate is as high as 9% [17,18]. These figures were generated by an
American study by Trussell [18] and are frequently utilised in Australian
literature. The typical-use rate is most commonly attributed to incorrect
or inconsistent use [2]. Thus, unplanned pregnancy is an important risk
for women taking the COCP to consider. There is little data to suggest
that sound knowledge of the COCP correlates to improved behavioural
changes and related outcomes such as unintended pregnancies [19,20].
Nevertheless, a better understanding of this common medication
is likely to be a significant contributing factor in the reduction of the
current failure rate which is why studies assessing women’s knowledge
of the COCP are important.
Research conducted in a diverse range of settings has indicated that
women’s knowledge of the COCP is generally poor [11,19,21-24]. A
comprehensive search of the current literature, however, revealed a
paucity of studies focusing on such knowledge amongst rural Australian
women, with only one Australian study focusing on women’s knowledge
of the COCP from a national perspective [11]. Furthermore, there
were no international studies focusing on a rural perspective in their
study populations. As such, this study aimed to evaluate the level of
knowledge women attending an Australian rural general practice have
regarding the COCP. The extent of knowledge was assessed through
several domains including: COCP use and effectiveness, mechanism of
action, and the potential risks and benefits of COCP use.
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Methods
Participants
Participants eligible for inclusion were women of reproductive age,
between 18 and 50 years, who were patients of a New South Wales
rural general practice, and who attended the practice during the study
period. Women who were currently using or had previously used the
COCP were invited to participate, as were women who had never taken
the COCP. Male patients and women taking a progesterone-only oral
contraceptive were excluded from this study due to the nature of the
research question. A total of 80 responses were collected and all were
used in data analysis.
Study design and survey
This study utilised an observational study design through the provision
of a survey to participants. The survey included two basic demographic
questions (age and level of education) and five questions assessing
personal COCP usage patterns. The questions assessing knowledge
covered several domains including: COCP use and effectiveness,
mechanism of action, and the potential risks and benefits of COCP use.
Additionally, participants were asked about their information sources
regarding the COCP.
Recruitment and data collection
Women attending the medical practice self-selected to complete the
survey. Participant information sheets were attached to each survey
and were made available at the reception desk of the practice. Posters
advertising the survey were also displayed in the waiting room area.
Participation was entirely voluntary and anonymous, with consent
being implied from completion of the survey. Completed surveys were
returned to a secure box at the reception desk, with access to returned
surveys and subsequent generated data being limited exclusively to
the lead researcher. Data collection occurred between October and
December 2014.
Ethics approval was granted by the University of Wollongong (UoW)
Human Research Ethics Committee in collaboration with the UoW
Graduate School of Medicine.
Statistical analysis
Survey data was processed using Microsoft Excel™. P-values were
calculated for correct scores between current and previous COCP users
using z-scores with a significance level of ≤ 0.05.
A “total knowledge score” was also calculated for each participant by
combining the total marks for questions 8, 10, and 11 of the survey,
where one mark was awarded to each correct response. Question 8
comprised a total of 6 sub-questions, question 10 comprised 13 and
question 11 had 15. As such, the maximum possible score for these
questions was 34. The mean total knowledge score was subsequently
calculated by averaging the values amongst all the participants. The
total knowledge scores of current COCP users versus previous users
were analysed using the Mann-Whitney “U test” with a significance
level of ≤ 0.05.
For the purpose of this study, a score of 80% or above for each individual
response item was designated as an adequate level of knowledge.

Results
Sample characteristics
In total, 80 responses were received during the study period. Table 1
shows basic demographic information of the study participants. The
mean age of the sample was 32.1 years (standard deviation = 8.8).
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Personal COCP usage information
Of the respondents, 98% (n = 78) had taken the COCP at some point
in their lives (question 3 of the survey). Further information regarding
usage for women who had previously or were currently taking the
COCP is listed in Table 2. Women who had never taken the COCP were
not required to complete these questions (questions 4 to 7).
Knowledge domains
1. COCP use and effectiveness
Participants were asked to complete questions that assessed their
general knowledge of the COCP and of what factors may reduce the
COCPs contraceptive effect.
In terms of general knowledge (question 8 of the survey), 96% of
participants correctly identified that the COCP needs to be taken every
day to serve as effective contraceptive, with 94% correctly identifying
that it should be taken at the same time every day. Only 28% of women
were aware that the COCP is not the most effective contraceptive
currently available with 13% of current COCP users selecting the
correct answer (compared to 35% of previous users).
Of the factors that may reduce the contraceptive effect of the COCP
(question 10), missing one active pill by more than 12 hours and
missing more than one active pill was correctly identified by 84% and
94% of women respectively. Other factors that potentially reduce
contraceptive effect (with percentage of participants selecting the
correct response in brackets) are as follows: St John’s wort (20%),
epilepsy medications (14%), vomiting (79%), and severe diarrhoea
(61%). Two-thirds of women incorrectly identified that antibiotics
(other than rifampicin and rifabutin) may be a factor that reduces
contraceptive benefit. There was no significant difference in the
number of participants selecting the correct response between
current and previous COCP users for each of the factors investigated.
Participant responses are further detailed in Table 3.
2. Mechanism of action
Only 58% of women surveyed correctly identified that the COCP acts
to prevent ovulation; this represented 44% of current COCP users
and 64% of previous COCP users. Furthermore, only 3% of the study
sample correctly identified all three mechanisms of action (preventing
ovulation, thickening of cervical mucus, and helping to prevent
adherence of the embryo to the endometrium).
3. Risks and benefits of COCP use
Frequencies of responses to questions assessing knowledge of the
potential risks and benefits of the COCP are shown in Table 4. The
conditions in which COCP use may be beneficial (with the percentages
of participants selecting the correct responses listed in brackets) were
as follows: menstrual disturbances (60%), acne (56%), endometriosisassociated pain (28%), ectopic pregnancy (9%), and ovarian and
endometrial cancer (6%). Fifty-nine percent of women correctly
identified that the COCP has no effect on the risk of contracting a
sexually transmitted infection (STI). Furthermore, weight gain was
incorrectly identified as a risk associated with taking the COCP by
75% of women with only 5% of participants selecting the correct
answer of “no effect”. COCP use increases the risk of cardiovascular
disease which 39% of women correctly identified. For the majority of
these questions, “don’t know” was the response selected by a large
proportion of participants.
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Table 1. Demographic information of sample (n = 80).

Variable
Q1. Age (years)
18-20
21-24
25-30
31-34
35-40
40-50
Q2. Education level
Year 10
Year 12
Undergraduate degree
Postgraduate degree
TAFE qualification
Other

Table 2. Usage information for women who are currently using or have
previously used the COCP.

Variable
Q4. Current COCP usage (n = 78)
Yes
No
Q5. Duration of COCP usage (n = 77)
< 1 year
1 – 5 years
5 – 10 years
> 10 years
Q6. Has an active tablet ever been
missed? (n = 78)
Yes
No
Don’t Know
Q7. Frequency of missing an active
tablet (n = 77)
Never
Only one time
Once a year
Once every few months
Once a month
Once a week

n (%)
8 (10%)
17 (21%)
10 (13%)
17 (21%)
11 (14%)
17 (21%)
18 (23%)
24 (30%)
16 (20%)
6 (8%)
12 (15%)
4 (5%)

n (%*)
23 (29%)
55 (69%)
5 (6%)
29 (36%)
17 (21%)
26 (33%)
64 (80%)
13 (16%)
1 (1%)
12 (15%)
4 (5%)
11 (14%)
30 (38%)
16 (20%)
4 (5%)

* Percentages calculated using the total sample (n = 80)

Table 3. Participant responses to general knowledge questions relating to the COCP and factors that may reduce its contraceptive action.

Yes

Q8. General knowledge (* indicates the correct answer)
The pill needs to be taken every day to be an *77 (96%)
effective contraceptive
The pill should be taken at approximately the *75 (94%)
same time every day
It is acceptable to continue taking active
*43 (54%)
tablets without taking the inactive tablets in
between
The pill is the most effective form of
44 (55%)
contraception currently available when used
correctly
It is possible to fall pregnant while taking the *63 (79%)
pill even with perfect use
It is important to take a break from using the 26 (33%)
pill

No

Don’t know No
Number of
response current COCP
users correct
(n = 23)

Number of
P-value
previous COCP (significance
users correct ≤ 0.05)
(n = 55)

1
(1%)
3 (4%)

-

2 (3%)

22 (96%)

53 (96%)

0.88

2 (3%)

-

23 (100%)

51 (93%)

0.18

16 (20%)

21 (26%)

-

12 (52%)

31 (56%)

0.73

*22 (28%)

14 (18%)

-

3 (13%)

19 (35%)

0.054

10 (13%)

6 (8%)

1 (1%)

16 (70%)

45 (82%)

0.23

*20 (25%)

34 (43%)

-

6 (26%)

14 (25%)

0.95

Q10. Factors that may reduce the contraceptive benefit of the COCP (* indicates the correct answer)
Missing one active pill by less than 12 hours
Missing one active pill by more than 12 hours
Missing more than one active pill
Missing one or more inactive pill/s
St John’s Wort herbal preparation
Epilepsy medications such as phenytoin or
carbamazepine
Vomiting
Severe diarrhoea
Smoking
Antibiotics such as rifampicin and rifabutin
Other antibiotics
(When taken without side-effects like
vomiting/diarrhoea)
Minor alcohol consumption
(e.g. an occasional alcoholic drink/s not on a
regular basis)
Excessive alcohol consumption
(e.g. drinking amounts that cause vomiting,
diarrhoea, poor concentration or memory, or
significant liver damage)

25 (31%)
*67 (84%)
*75 (94%)
22 (28%)
*16 (20%)
*11 (14%)

*34 (43%)
6 (8%)
1 (1%)
*43 (54%)
9 (11%)
3 (4%)

17 (21%)
7 (9%)
3 (4%)
14 (18%)
55 (69%)
66 (83%)

4 (5%)
1 (1%)
1 (1%)
-

11 (48%)
19 (83%)
23 (100%)
14 (61%)
5 (22%)
3 (13%)

23 (42%)
48 (87%)
51 (93%)
28 (51%)
11 (20%)
8 (15%)

0.62
0.58
0.18
0.42
0.86
0.86

*63 (79%)
*49 (61%)
6 (8%)
*53 (66%)
53 (66%)

5 (6%)
10 (13%)
*36 (45%)
3 (4%)
*2 (3%)

12 (15%)
21 (27%)
38 (48%)
24 (30%)
25 (31%)

-

19 (83%)
15 (65%)
9 (39%)
14 (61%)
0 (0%)

44 (80%)
34 (62%)
26 (47%)
38 (69%)
2 (4%)

0.79
0.78
0.51
0.48
0.35

6 (8%)

*52 (65%)

22 (28%)

-

17 (74%)

35 (64%)

0.38

*43 (54%)

13 (16%)

24 (30%)

-

10 (43%)

32 (58%)

0.23
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Table 4. Participant responses regarding effects of the COCP on level of risk for various conditions.

Q11.

Decreases

No effect

Increases

Don’t
know

No
response

Number
of current
COCP
users
correct
(n=23)

Number of P-value
(significance
previous
≤ 0.05)
COCP
users
correct
(n=55)

Ectopic pregnancy

*7 (9%)

18 (23%)

11 (14%)

44 (55%)

-

2 (9%)

4 (7%)

0.83

Birth defects

2 (3%)

*33 (41%)

8 (10%)

37 (46%)

-

4 (17%)

29 (53%)

0.004

Infertility

3 (4%)

*30 (38%)

14 (18%)

33 (41%)

-

9 (39%)

21 (38%)

0.94

Cardiovascular disease
(stroke, hypertension, clots)

2 (3%)

14 (18%)

*31 (39%)

33 (41%)

-

10 (43%)

21 (38%)

0.66

Benign breast disease

*4 (5%)

17 (21%)

16 (20%)

42 (53%)

1 (1%)

0 (0%)

4 (7%)

0.18

Functional ovarian cysts

*9 (11%)

12 (15%)

11 (14%)

47 (59%)

1 (1%)

4 (17%)

5 (9%)

0.29

Endometriosis-associated pain

*22 (28%)

9 (11%)

3 (4%)

45 (56%)

1 (1%)

8 (35%)

14 (25%)

0.41

Breast cancer

4 (5%)

17 (21%)

*18 (23%)

41 (51%)

-

6 (26%)

13 (22%)

0.82

Ovarian cancer

*5 (6%)

18 (23%)

11 (14%)

46 (58%)

-

2 (9%)

3 (5%)

0.59

Endometrial cancer

*5 (6%)

18 (23%)

7 (9%)

50 (63%)

-

1 (4%)

4 (7%)

0.63

Menstrual disturbances

*48 (60%)

6 (8%)

9 (11%)

13 (16%)

4 (5%)

12 (52%)

35 (64%)

0.35

Acne

*45 (56%)

4 (5%)

14 (18%)

16 (20%)

1 (1%)

11 (48%)

33 (60%)

0.32

Weight gain

1 (1%)

*4 (5%)

60 (75%)

13 (16%)

2 (3%)

1 (4%)

3 (5%)

0.84

Pelvic inflammatory disease

*6 (8%)

14 (18%)

9 (11%)

50
(63%)

1 (1%)

2 (9%)

4 (7%)

0.83

Sexually transmitted infections

4 (5%)

*47 (59%)

7 (9%)

20 (25%)

2 (3%)

11 (48%)

36 (65%)

0.12

* Indicates the correct answer

Question 12 of the survey asked women to identify factors that can
potentially increase a women’s risk of thromboembolism while taking
the COCP. The most frequently identified risk factors were smoking and
obesity (selected by 74% and 69% of participants, respectively). Only
38% correctly identified all three risk factors, which also includes age
greater than 35 years [11,14].
Information sources
Participants were asked where they source information regarding the
COCP for question 13 of the survey. “General practitioner” was the
most frequently selected option at 90% (n = 72). Further response
details are shown in Figure 1.

Total knowledge score
The mean total knowledge score for all participants was 14.4 (SD =
4.86) out of a possible 34 (range = 5 to 26). The mean total knowledge
score for current COCP users was 14.0 (SD = 4.81), with previous COCP
users achieving a mean score of 14.8 (SD = 4.75). Women who had
never used the COCP achieved a mean total knowledge score of 6.5.
There was no significant difference in total knowledge score between
current and previous users of the COCP (p = 0.56).

General Practitioner
Product Information Sheet
Pharmacist
Internet
Family members
Friends
Nurse
Other Doctor (e.g. Gynaecologist)
Community Health Clinic
Other (e.g. school education sessions)
0

10

20

30

40

50

60

Percentage of participants

Figure 1. Survey participants’ information sources regarding the COCP.
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Discussion
This study has found deficiencies in women’s knowledge of the COCP
in all domains that were assessed. This finding is consistent with the
available literature [11,19,21-24]. For the purpose of this study, a score
of 80% or above for each individual response item was designated as
an adequate level of knowledge. The rationale for stating an arbitrary
value such as this was influenced by a recent systematic review by
Hall et al. [19]. Though many studies concluded women have a poor
level of knowledge regarding oral contraceptives, Hall et al. stated that
of the studies they included for review, “what constituted deficient
or adequate knowledge was not clearly defined”. The majority of
women did not score above the required 80% correct responses to be
considered adequate knowledge. No significant differences were found
in the number of correct responses per question between current COCP
users and previous users except for one question regarding whether
the COCP has an effect on the risk of birth defects occurring (p = 0.004).
Furthermore, the total knowledge score for both current and previous
COCP users was less than 50% of the possible maximum score.
Several key findings discussed below stand out as being important
focus areas for improved contraceptive counselling.
COCP use and effectiveness
This study revealed that 55% of women believe the COCP is the most
effective form of contraception currently available when used correctly,
with only 13% of current COCP users correctly identifying that it is not.
Examples of contraception that have a better failure rate profile than
the COCP include long-acting reversible contraceptives (LARC) such as
the implantable rod (typical and perfect-use failure rate 0.05%), and
intrauterine devices such as the Mirena (typical and perfect-use failure
rate 0.2%) [17].
Women were not aware that antibiotics (other than rifampicin and
rifabutin) were no longer considered to have a negative impact on the
contraceptive effect of the COCP [25], with 66% of women indicating
that taking antibiotics (without side effects such as vomiting and
diarrhoea) would reduce the contraceptive effect of the COCP.
There were mixed results regarding whether it is important to take a
break from the COCP with 25% of women correctly identifying there
is no requirement for a break. Interestingly, Philipson, Wakefield, and
Kasparian [11] found that 25.6% of their participants thought that
it was healthy to stop COCP use for a while (length of time was not
stipulated in the question).
Mechanism of action
Only 58% of women correctly identified the main mechanism by which
the COCP works, with 3% correctly identifying all three mechanisms. A
systematic review by Hall et al. [19] found that understanding of the
mechanism of action is infrequently assessed in similar studies. A study
by Rajasekar and Bigrigg [23] not included in the aforementioned review
found that 81.5% of women understood that the oral contraceptive
prevented ovulation every month, but that 32% also thought that it
killed sperm.
Risks of COCP use
Of the study participants, 39% correctly identified that the COCP
increases the risk for cardiovascular disease (hypertension, stroke, and
other thromboembolic events). Similarly, Philipson, Wakefield, and
Kasparian [11] found that 46.5% women identified an increase in blood
clots. Although 74% of women in our study identified smoking as a
factor that when combined with the COCP increases thromboembolism
risk further, only 38% of women correctly identified all three risk
factors (obesity, age over 35 years, and smoking).

Women appear to erroneously believe that the COCP causes weight
gain (75% of respondents). A causal relationship has never been
established. A Cochrane Review has found there is no significant
difference in weight change between placebo and those taking
combined contraceptives, though further research was indicated [26].
Previous studies suggest similar results. Fletcher, Bryden, and Bonin
[27] found that 30.6% of respondents were concerned about weight
gain on the pill, with 23.4% of respondents reporting weight gain as
an experienced side effect. Gaudet et al. [28] found that 51.5% of
respondents thought weight would increase on the pill.
Only 59% of women were aware that the COCP has no effect on
contracting STIs, with 48% of current COCP users identifying the correct
answer. This result is lower than that found by Philipson, Wakefield,
and Kasparian [11] with 81.3% of their respondents identifying the
correct answer.
Benefits of COCP use
There was a low level of understanding regarding decreased ovarian and
endometrial cancer risk, but a better (though still low) understanding
that COCP use can improve acne and menstrual disturbances. Poor
understanding about COCP benefits appears consistent among studies
with Philipson, Wakefield, and Kasparian [11] finding 13.7% correctly
identified that COCP use decreases ovarian cancer risk, with 10%
identifying decreased risk of endometrial cancer.

Study limitations
Noting that approximately 29% of this study sample is currently taking
the COCP, one might consider that knowledge would be forgotten after
having ceased the COCP or after changing contraceptive methods.
Additionally, it cannot be expected that women will remember all
details relating to the COCP, as with any medication. Significant
limitations of this study include the small response rate, which is likely
due to the self-selection of participants. A self-selection bias may also
exist. We can see from the results that there were very few women
who had never taken the pill completing the survey. We must consider
whether this is a true representation, or whether this may reflect the
fact that women who have previously taken or are currently taking
the COCP are more likely to complete the survey (perhaps due to a
perceived familiarity with the topic). As the study was conducted in
a general practice, a bias may also exist towards women who are
likely to attend such medical facilities. An additional limitation of this
study is that data was generated out of a single general practice and
therefore the results may reflect specific factors associated with the
GPs working there. Due to how the study was implemented, it cannot
be determined if the participants had ever received contraceptive
counselling from the practitioners within this centre, or whether a
single or multiple GPs from this practice may have been involved in
the counselling and prescribing of the COCP. At the time the study
was conducted, seven GPs were working within the practice and
so participants are likely patients of a number of these GPs with no
particular focus on an individual practitioner’s patient list. Both the
self-selection and single-centre nature of this study means that the
results cannot be generalised. The survey was developed after a
review of current literature and did not come from a validated source.
Assessment of the reading level of the survey and a pilot study prior to
data collection would improve the validity of the findings. Additionally,
statistical analysis was limited to current and previous COCP users as
the sample of participants who had never used the COCP was too small
to allow reliable calculations.

Implication for clinical practice and future directions
A recent analysis of the Bettering the Evaluation and Care of Health
(BEACH) data by Mazza et al. [1] found that COCP prescribing is a
common focus of many GP consultations concerning contraceptive
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management. Our study also indicated that GPs are the main source of
information regarding the COCP. Given that the COCP is a prescription
medication, routine medical consultations are required and offer
ample opportunity for medical practitioners to ensure appropriate use
and knowledge of the COCP. This is especially so since a total of 54%
of participants in our study indicated they have been or were using
the pill for more than five years. In their study assessing Australian
women’s knowledge of the COCP, Philipson, Wakefield, and Kasparian
[11] found a positive correlation between duration of pill usage and
level of knowledge.
Although our study suggested that GPs are the main source of
information regarding the COCP, there were many other information
sources identified and so we cannot assume the subsequent level of
knowledge of the surveyed participants is the result of GP intervention
alone. Therefore, other healthcare professionals that may provide
COCP counselling have a role in helping to improve women’s knowledge
of the COCP. Given that the Internet, friends, and family members were
also important information sources for women regarding the COCP,
awareness and appropriate counselling is also necessary to identify
and address any misinformation that women may have obtained from
these sources.
This study provides a unique perspective in that it assesses rural
Australian women’s knowledge of the COCP. The aforementioned study
by Philipson, Wakefield, and Kasparian [11], whose data collection was
generated randomly from each state, was the only other Australian
study identified after examination of the literature. As our study was
limited to a rural general practice setting, future research may wish to
expand on this data by investigating other rural practices or compare
results to metropolitan practices.
Rural Australians experience poorer health outcomes compared to
their metropolitan counterparts [29,30]. Health literacy is likely a
contributing factor to such outcomes [30]. An analysis of the Adult
Literacy and Life Skills Survey data from 2006 by the Australian Bureau
of Statistics shows that health literacy levels are low across the board –
42% of Australian urban populations were shown to have a literacy level
of 3 (considered an adequate level) or greater; 38% and 39% of inner
regional and remote populations, respectively also demonstrated a
literacy level of 3 or greater. The outer regional populations possessed
the lowest levels of people demonstrating a literacy level of 3 or
greater at 36% [31]. In the context of the clinical environment, there
is a paucity of literature available, but one recent study by Wong et
al. [32] comparing health literacy of patients attending both a rural
and an urban rheumatology practice found no significant difference
between these groups. Despite research showing differences in health
outcomes between rural and metropolitan populations of Australia
[29,30], studies comparing the knowledge and health literacy of rural
and metropolitan patients, particularly in relation to medications,
proved difficult to find so we cannot extrapolate the findings of the
current study to comment on whether a general knowledge deficit
exists.
Since this study was designed only to assess women’s level of
knowledge about the COCP, and not factors associated with level of
knowledge, further studies regarding what factors influence knowledge
are also important. These may include factors relating to the primary
care setting, such as: impact of consultation timing; exploring the
discussions and resources used during COCP consultations and whether
counselling deficiencies exist; assessing what information healthcare
professionals deem clinically relevant or applicable on an individual
patient basis, and whether this impacts upon what information is
provided to patients and therefore what knowledge base they retain.
Additional studies may wish to investigate the effectiveness of the
product information sheet for the COCP, or whether women believe
COCP information is easily accessible and where this can be obtained
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(for example, what limits women’s access to information from
pharmacies or community health clinics). Future studies may also wish
to explore whether rural specific issues (for example, more limited
access to healthcare providers) play a role.
Furthermore, additional studies that evaluate practical strategies
for improving knowledge and information retention should also
be undertaken. In the systematic review by Hall et al. [19] only four
studies assessed interventions and their impact on contraceptive pill
knowledge. Three of the four studies noted improved knowledge in at
least one domain, highlighting that an array of additional educational
materials may be beneficial in improving counselling sessions [19].
As more Australian-specific data accumulates about women’s
knowledge of the COCP, better public health initiatives and education
strategies can be implemented to improve outcomes. The results of this
study may encourage healthcare professionals to better understand
and review areas of their own counselling sessions. Improvements
may be achieved through better addressing how to use the COCP, what
will affect its contraceptive benefit, and common misconceptions.
Additionally, healthcare professionals can be assured they have
provided appropriate informed consent by discussing risks, benefits,
and alternative options [33]. In the long term, this may eventually lead
to improvements in the typical failure rate of the COCP and reduce the
rate of unintended pregnancies.

Conclusion
The women surveyed in this study appear to have substantial gaps in
their knowledge of the COCP despite a high prevalence and duration of
usage. Although many other sources were also utilised for information
on the COCP, GPs were the main source of information. As such, this
study provides insight into specific knowledge areas that require
further education and clarification during COCP counselling sessions
to encourage improved knowledge of the COCP by women, particularly
those in the rural Australian general practice setting.
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